Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

Fig. 5

Serotonin (5-HT) deafferentation in APPSWE/PS1ΔE9 (APP/PS1) mice with 5,7-dihydroxytryptamine (DHT)-induced lesions. Three-month-old APP/PS1 mice were lesioned with DHT and, together with sham-operated mice, allowed to survive until the age of 9 months. Neocortex samples were analysed with high-performance liquid chromatography, and data showed a 60–65% reduction of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA). Data are presented as mean ± SEM and were analysed by unpaired, two-tailed Mann-Whitney U test. ****p < 0.0001

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193